Ainos (AIMD) 10-Q 20 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 20, 2017
Document Information [Line Items]
Entity Registrant Name	AMARILLO BIOSCIENCES INC
Entity Central Index Key	1,014,763
Trading Symbol	amar
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		23,156,563
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false

Balance Sheets (Current Period

Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 145,029	$ 134,125
Inventory		14,700
Advance to related party	28,584	37,835
Prepaid expense and other current assets	38,718	75,739
Total current assets	212,331	262,399
Patents, net	179,208	156,063
Property and equipment, net	31,302	44,214
Total assets	422,841	462,676
Liabilities and Stockholders' Deficit
Accounts payable and accrued expenses	175,339	165,502
Accrued interest - related parties	10,018	3,259
Advance from related party	187,500	187,500
Stock subscription deposit	142,107
Customer deposits – related parties		124,833
Convertible note payable – related party	886,481	791,481
Total current liabilities	1,401,445	1,272,575
Total liabilities	1,401,445	1,272,575
Commitments and contingencies
Stockholders' deficit
Preferred stock, $0.01 par value: Authorized shares - 10,000,000, Issued and outstanding shares – 0 at December 31, 2016 and December 31, 2015
Common stock, $0.01 par value: Authorized shares - 100,000,000, Issued and outstanding shares – 23,078,668 and 21,916,143 at September 30, 2017 and December 31, 2016, respectively	230,787	219,161
Additional paid-in capital	465,960	237,540
Accumulated deficit	(1,675,351)	(1,266,600)
Total stockholders' deficit	(978,604)	(809,899)
Total liabilities and stockholders’ deficit	$ 422,841	$ 462,676

Balance Sheets (Current Period3

Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares authorized (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	23,078,668	21,916,143
Common stock, shares outstanding (in shares)	23,078,668	21,916,143

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Sales – ACM			$ 250,502
Sales – Herbs				4,400
Total revenues			250,502	4,400
Cost of revenues:
Product sales			58,801	5,100
Total cost of revenues			58,801	5,100
Gross Margin			191,701	(700)
Operating expenses:
Research and development expenses
Selling, general and administrative expenses	230,875	178,470	592,822	434,176
Total operating expenses	230,875	178,470	592,822	434,176
Operating loss	(230,875)	(178,470)	(401,121)	(434,876)
Other income (expense):
Interest expense	(1,929)	(798)	(7,630)	(2,257)
Net loss	$ (232,804)	$ (179,268)	$ (408,751)	$ (437,133)
Basic and diluted net loss per share (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average shares outstanding – basic and diluted (in shares)	22,789,370	21,394,810	22,500,663	20,871,635

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net cash used in operating activities:	$ (188,526)	$ (426,988)
Cash flows from investing activities:
Investment in equipment		(47,685)
Investment in patents	(39,945)	(54,483)
Net cash used in investing activities	(39,945)	(102,168)
Cash flows from financing activities:
Proceeds from private placement offering	144,375	421,875
Proceeds from convertible note payable – related party	95,000	262,500
Net cash provided by financing activities	239,375	684,375
Net change in cash	10,904	155,219
Cash and cash equivalents at beginning of period	134,125	21,138
Cash and cash equivalents at end of period	145,029	176,357
Supplemental disclosure of cash flow information
Cash paid for interest		1,066
Cash paid for income taxes
Noncash transactions:
Common stock shares issued for services	10,671
Conversion of accounts payable – related party to convertible note payable – related party		144,426
Conversion of notes payable – related party to convertible note payable – related party		$ 384,555

Note 1 - Organization and Busin

Note 1 - Organization and Business	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Business. Amarillo Biosciences, Inc. (the "Company” or “ABI”), a Texas corporation formed in 1984, The Medical Division opened a diabetic treatment center in Hong Kong in February 2017, 1 2

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of presentation. The accompanying financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10 December 31, 2016, April 17, 2017, not nine September 30, 2017 not may December 31, 2017.

Note 3 - Financial Condition

Note 3 - Financial Condition	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Financial Condition [Text Block]	3. Financial Condition. These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not no The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not There can be no may may may

Note 4 - Common Stock

Note 4 - Common Stock	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	4. Common Stock. The shareholders have authorized 100,000,000 September 30, 2017, 28,731,754 23,078,668 4,817,305 two 757,904 On March 10, 2016, the Company to enter into private placements for the sale of up to 5,000,000 2016 2 $.1875 $937,500 On September 30, 2016, 2016 2 of unregistered securities. The Private Placement 2016 2 10,000,000 $.1875 $1,875,000. one 1 During the first 2017, 270,000 $.1875 $50,625. No second 2017. third 2017, 500,000 $.1875 $93,750. 200,000 $.1875 $37,500. On January 3, 2017, Stephen T. Chen, CEO, and Bernard Cohen, CFO/VP, received 145,405 19,387 2016 $42,500. $.2579 December 20, 2016. December 31, 2016. On April 3, 2017, 76,095 10,146 Q1 2017 $21,250. $.2464 March 31, 2017. On July 7, 2017, 74,552 9,940 Q2 2017 $21,250. $.2515 quarter ended June 30, 2017. On August 1, 2017, 57,000 $.1875 ’ fees in the amount of $10,671. In September 2017, sell approximately $1.4M $0.1875 7,579,059 10% $142,107 no On October 26, 2017, 2016 2 April 26, 2018 5,000,000 $.1875 $2,812,500. October 31, 2017,

Note 5 - Convertible Notes Paya

Note 5 - Convertible Notes Payable - Related Party	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Convertible Debt [Text Block]	5. Convertible Notes Payable – Related Party. December 31, 2016, $144,426 January 11, 2016, .75%, may $.168 On March 18, 2016, $262,500 ’s Private Placement Convertible Note Security Offering entitled Private Placement 2016 1 March 10, 2016). .65% $.1875 On June 30, 2016, $384,555 two – Related Party. The Convertible Note is due on demand, is unsecured, bears interest at the Short-Term Applicable Federal Rate of .64% $.1875 On May 25 , 2017, $70,000 three .86% $.1875 On September 1 , 2017, $25,000 one .96% $.1875 September 30, 2017 December 31, 201 6 Convertible Note payable – related party $ 144,426 $ 144,426 Convertible Note payable – related party 262,500 262,500 Convertible Note payable – related party 384,555 384,555 Convertible Note payable – related party 70,000 - Convertible Note payable – related party 25,000 - Convertible Notes payable – related party $ 886,481 $ 791,481

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6. Related Party Transactions. On May 23, 2016, $3,000,681 $91,968 may $37,500 September 1, 2017. may one 1% September 30, 2017, $28,584 In April 2016, $187,500 1,000,000 2016 2 September 30, 2017, not not On December 20, 2016, January 1, 2017, $90,000 $75,000 $65,000 annum and $10,000 15th 31st first September 30, 2017, 535,525 $122,500. September 30, 2017, $21,250 Q3 2017 not On May 25 2017, $70,000 three .86% $.1875 On September 1 2017, $25,000 one .96% $.1875 On September 29, 2017, $13,000 to CTBC Bank Co Ltd in Taipei, Taiwan for the purpose of funding a cash account for the Company to begin direct branch business operations in the country. The minimum deposit amount required to open the account was NTD 300,000 $10,000 $13,000

Note 7 - Subsequent Events

Note 7 - Subsequent Events	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	7. Subsequent Events On October 6, 2017, 68,731 9,164 Q3 2017 $21,250. $.2728 $21,250 September 30, 2017. On October 26, 2017, 2016 2 April 26, 2018 5,000,000 $.1875 $2,812,500. October 31, 2017,

Note 5 - Convertible Notes Pa13

Note 5 - Convertible Notes Payable - Related Party (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Convertible Notes Payable, Related Parties [Table Text Block]	September 30, 2017 December 31, 201 6 Convertible Note payable – related party $ 144,426 $ 144,426 Convertible Note payable – related party 262,500 262,500 Convertible Note payable – related party 384,555 384,555 Convertible Note payable – related party 70,000 - Convertible Note payable – related party 25,000 - Convertible Notes payable – related party $ 886,481 $ 791,481

Note 4 - Common Stock (Details

Note 4 - Common Stock (Details Textual) - USD ($)	Oct. 26, 2017	Oct. 06, 2017	Aug. 01, 2017	Jul. 07, 2017	Apr. 03, 2017	Jan. 03, 2017	Mar. 10, 2016	Sep. 30, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Common stock, shares authorized (in shares)								100,000,000	100,000,000			100,000,000		100,000,000
Common Stock, Shares Outstanding and Reserved								28,731,754	28,731,754			28,731,754
Common Stock, Shares, Issued								23,078,668	23,078,668			23,078,668		21,916,143
Common Stock, Shares Subscribed but Unissued								4,817,305	4,817,305			4,817,305
Common Stock, Capital Shares Reserved for Future Issuance								757,904	757,904			757,904
Amount of Private Placement							$ 937,500						$ 1,875,000
Proceeds from Issuance of Private Placement									$ 93,750		$ 50,625	$ 144,375	$ 421,875
Stock Subscription Deposit								$ 142,107	142,107			$ 142,107
Subsequent Event [Member]
Shares Authorized During Period, Private Placement	5,000,000
Amount of Private Placement	$ 2,812,500
Chief Executive Officer [Member]
Proceeds from Issuance of Private Placement									$ 37,500
Deferred Compensation Arrangement with Individual, Shares Issued				74,552	76,095	145,405
Chief Executive Officer [Member] | Subsequent Event [Member]
Deferred Compensation Arrangement with Individual, Shares Issued		68,731
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Shares Issued				9,940		19,387
Chief Financial Officer [Member] | Subsequent Event [Member]
Deferred Compensation Arrangement with Individual, Shares Issued		9,164
The Chief Executive Officer and Chief Financial Officer [Member]
Shares Issued, Price Per Share				$ 0.2515	$ 0.2464	$ 0.2579
Deferred Compensation Arrangement with Individual, Shares Issued					10,146
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued				$ 21,250	$ 21,250	$ 42,500
The Chief Executive Officer and Chief Financial Officer [Member] | Subsequent Event [Member]
Shares Issued, Price Per Share		$ 0.2728
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued		$ 21,250
Finders [Member]
Shares Issued, Price Per Share			$ 0.1875
Stock Issued During Period, Shares, Issued for Services			57,000
Stock Issued During Period, Value, Issued for Services			$ 10,671
Private Placement [Member]
Sale of Stock, Price Per Share							$ 0.1875
Share Price													$ 0.1875
Stock Issued During Period, Shares, New Issues									500,000	0	270,000
Shares Issued, Price Per Share								$ 0.1875	$ 0.1875		$ 0.1875	$ 0.1875
Private Placement [Member] | Subsequent Event [Member]
Sale of Stock, Price Per Share	$ 0.1875
Private Placement [Member] | Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues									200,000
Shares Issued, Price Per Share								$ 0.1875	$ 0.1875			$ 0.1875
Subscription Agreement [Member]
Common Stock, Shares Subscribed but Unissued								7,579,059	7,579,059			7,579,059
Share Price								$ 0.1875	$ 0.1875			$ 0.1875
Common Stock, Value, Subscriptions								$ 1,400,000	$ 1,400,000			$ 1,400,000
Common Stock, Subscriptions, Deposit, Percentage								10.00%	10.00%			10.00%
Stock Subscription Deposit								$ 142,107	$ 142,107			$ 142,107
Stock Issued During Period, Value, New Issues								$ 0
Maximum [Member]
Shares Authorized During Period, Private Placement							5,000,000						10,000,000

Note 5 - Convertible Notes Pa15

Note 5 - Convertible Notes Payable - Related Party (Details Textual) - USD ($)	Sep. 30, 2017	Sep. 01, 2017	May 25, 2017	Dec. 31, 2016	Jun. 30, 2016	Mar. 18, 2016
Notes Payable, Convertible, Related Parties, Classified Current	$ 886,481			$ 791,481
Chief Executive Officer [Member] | First Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	144,426			$ 144,426
Debt Instrument, Interest Rate, Stated Percentage				0.75%
Debt Instrument, Convertible, Conversion Price				$ 0.168
Chief Executive Officer [Member] | Second Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	262,500			$ 262,500
Chief Executive Officer [Member] | Second Issuance [Member] | Private Placement Convertible Promissory Notes [Member]
Notes Payable, Convertible, Related Parties, Classified Current						$ 262,500
Debt Instrument, Interest Rate, Stated Percentage						0.65%
Debt Instrument, Convertible, Conversion Price						$ 0.1875
Chief Executive Officer [Member] | Third Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	384,555			384,555	$ 384,555
Debt Instrument, Interest Rate, Stated Percentage					0.64%
Debt Instrument, Convertible, Conversion Price					$ 0.1875
Chief Executive Officer [Member] | Fourth Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	70,000
Debt Instrument, Interest Rate, Stated Percentage			0.86%
Debt Instrument, Convertible, Conversion Price			$ 0.1875
Notes Payable, Related Parties, Current			$ 70,000
Chief Executive Officer [Member] | Fifth Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	$ 25,000
Debt Instrument, Interest Rate, Stated Percentage		0.96%
Debt Instrument, Convertible, Conversion Price		$ 0.1875
Debt Instrument, Face Amount		$ 25,000

Note 5 - Convertible Notes Pa16

Note 5 - Convertible Notes Payable - Related Party - Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Jun. 30, 2016
Convertible note payable – related party	$ 886,481	$ 791,481
First Issuance [Member] | Chief Executive Officer [Member]
Convertible note payable – related party	144,426	144,426
Second Issuance [Member] | Chief Executive Officer [Member]
Convertible note payable – related party	262,500	262,500
Third Issuance [Member] | Chief Executive Officer [Member]
Convertible note payable – related party	384,555	384,555	$ 384,555
Fourth Issuance [Member] | Chief Executive Officer [Member]
Convertible note payable – related party	70,000
Fifth Issuance [Member] | Chief Executive Officer [Member]
Convertible note payable – related party	25,000
Sixth Issuance [Member] | Chief Executive Officer [Member]
Convertible note payable – related party	$ 886,481	$ 791,481

Note 6 - Related Party Transa17

Note 6 - Related Party Transactions (Details Textual)	Sep. 29, 2017USD ($)	Sep. 01, 2017USD ($)$ / shares	Jan. 01, 2017USD ($)	May 23, 2016USD ($)	May 23, 2016TWD	Apr. 30, 2016USD ($)shares	Sep. 30, 2017USD ($)shares	Sep. 29, 2017TWD	May 25, 2017USD ($)$ / shares
Cash Funds to CTBC Bank Co Ltd	$ 13,000
Minimum Deposit Required to Open Account	10,000							TWD 300,000
Cash to Minimize Currency Translation Risk and to Cover Necessary Fees	$ 13,000
ACTS Global Healthcare, Inc. [Member]
Payments for Advance to Affiliate		$ 37,500		$ 91,968	TWD 3,000,681
Percentage to be Paid to Affiliate for Services Rendered				1.00%	1.00%
Prepaid Expense, Current							$ 28,584
Investor Related to Amarillo Biosciences (Hong Kong) Ltd. [Member] | Proceeds Received In Exchange for Potential Issuance of Common Stock [Member]
Related Party Transaction, Amounts of Transaction						$ 187,500
Investor Related to Amarillo Biosciences (Hong Kong) Ltd. [Member] | Potentially Issuable Common Stock For Cash [Member]
Stock Issuable Upon Receipt of Private Placement Memorandum | shares						1,000,000
Chief Executive Officer [Member]
Allocated Share-based Compensation Expense			$ 75,000
Chief Executive Officer [Member] | Related Party, Promissory Note, September 1, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage		0.96%
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 0.1875
Debt Instrument, Fee Amount		$ 25,000
Chief Executive Officer [Member] | Cash Bonus [Member]
Officers' Compensation			90,000
Chief Executive Officer [Member] | Related Party, Promissory Note [Member]
Notes Payable, Related Parties, Current									$ 70,000
Debt Instrument, Interest Rate, Stated Percentage									0.86%
Debt Instrument, Convertible, Conversion Price | $ / shares									$ 0.1875
Chief Financial Officer [Member]
Allocated Share-based Compensation Expense			10,000
Chief Financial Officer [Member] | Cash Bonus [Member]
Officers' Compensation			$ 65,000
The Chief Executive Officer and Chief Financial Officer [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares							535,525
Stock Issued During Period, Value, Share-based Compensation, Gross							$ 122,500
The Chief Executive Officer and Chief Financial Officer [Member] | Accounts Payable and Accrued Liabilities [Member]
Accrued Employee Benefits, Current							$ 21,250

Note 7 - Subsequent Events (Det

Note 7 - Subsequent Events (Details Textual) - USD ($)	Oct. 26, 2017	Oct. 06, 2017	Jul. 07, 2017	Apr. 03, 2017	Jan. 03, 2017	Mar. 10, 2016	Sep. 30, 2016	Sep. 30, 2017	Mar. 31, 2017
Amount of Private Placement						$ 937,500	$ 1,875,000
Private Placement [Member]
Shares Issued, Price Per Share								$ 0.1875	$ 0.1875
Sale of Stock, Price Per Share						$ 0.1875
Subsequent Event [Member]
Shares Authorized During Period, Private Placement	5,000,000
Amount of Private Placement	$ 2,812,500
Subsequent Event [Member] | Private Placement [Member]
Sale of Stock, Price Per Share	$ 0.1875
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Shares Issued			74,552	76,095	145,405
Chief Executive Officer [Member] | Private Placement [Member]
Shares Issued, Price Per Share								$ 0.1875
Chief Executive Officer [Member] | Subsequent Event [Member]
Deferred Compensation Arrangement with Individual, Shares Issued		68,731
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Shares Issued			9,940		19,387
Chief Financial Officer [Member] | Subsequent Event [Member]
Deferred Compensation Arrangement with Individual, Shares Issued		9,164
The Chief Executive Officer and Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Shares Issued				10,146
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued			$ 21,250	$ 21,250	$ 42,500
Shares Issued, Price Per Share			$ 0.2515	$ 0.2464	$ 0.2579
The Chief Executive Officer and Chief Financial Officer [Member] | Subsequent Event [Member]
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued		$ 21,250
Shares Issued, Price Per Share		$ 0.2728